Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
metamizole + pitofenone + fenpiverinium
- Development stage
- Unknown
- Lead developer
- Sanjivani Parenteral
- Modality
- Small Molecules
- Administration
- Intramuscular, Intravenous, Parenteral
01
Overview
Sanalgin Plus is a fixed-dose combination drug containing the non-opioid analgesic metamizole (dipyrone), the musculotropic spasmolytic pitofenone, and the anticholinergic agent fenpiverinium. Developed by Sanjivani Parenteral, it is formulated as an injection for the short-term treatment of acute, moderate-to-severe pain associated with smooth muscle spasms of the gastrointestinal tract, biliary tract, urinary tract, or uterus (such as renal colic, biliary colic, and dysmenorrhea). Metamizole acts primarily by inhibiting prostaglandin synthesis in the central nervous system, while pitofenone exerts a direct papaverine-like myotropic relaxing effect on smooth muscle, and fenpiverinium provides additional anticholinergic (antimuscarinic) spasmolytic activity. Together, these components act synergistically to relieve both pain and muscle spasms.
- Brand names
- Sanalgin Plus
- Other names
- dipyrone + pitofenone + fenpiveriniummetamizole + pitofenone + fenpiveriniummetamizole sodium + pitofenone hydrochloride + fenpiverinium bromide
02
Targets
AcetylcholinesteraseCHRM3 (M3)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on metamizole + pitofenone + fenpiverinium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on metamizole + pitofenone + fenpiverinium.